Abstract
Venous thrombosis is a common medical disorder affecting nearly one million Americans each year. This review will focus primarily on the formation of venous thrombosis as well as current and future treatment options. While the full pathophysiology of venous thrombosis is not known, recent evidence points to a role for von Willebrand Factor, platelets, and neutrophils in thrombus formation. Many laboratory and imaging tests may be used for the diagnosis of venous thrombosis (VTE), but risk factor identification and clinical examination should not be overlooked as they are vital in assuring accurate treatment and patient identification. Historically heparin followed by a vitamin K antagonist has been the standard of care for treatment of VTE, but increasing data involving factor Xa inhibitors and direct thrombin inhibitors may mean a shift in first-line therapy in the very near future. Invasive therapies such as catheter-directed thrombolysis have also shown promise in the treatment of venous thrombosis and will likely see increased use in the future.
Keywords: Venous thrombolism, pulmonary embolism, heparin, warfarin, EKOS, factor Xa inhibitors, direct thrombin inhibitors.
Current Drug Targets
Title:Pathophysiology and Pharmacologic Treatment of Venous Thromboembolism
Volume: 15 Issue: 2
Author(s): Jonathan Bain, Douglas R. Oyler, Susan S. Smyth and Tracy E. Macaulay
Affiliation:
Keywords: Venous thrombolism, pulmonary embolism, heparin, warfarin, EKOS, factor Xa inhibitors, direct thrombin inhibitors.
Abstract: Venous thrombosis is a common medical disorder affecting nearly one million Americans each year. This review will focus primarily on the formation of venous thrombosis as well as current and future treatment options. While the full pathophysiology of venous thrombosis is not known, recent evidence points to a role for von Willebrand Factor, platelets, and neutrophils in thrombus formation. Many laboratory and imaging tests may be used for the diagnosis of venous thrombosis (VTE), but risk factor identification and clinical examination should not be overlooked as they are vital in assuring accurate treatment and patient identification. Historically heparin followed by a vitamin K antagonist has been the standard of care for treatment of VTE, but increasing data involving factor Xa inhibitors and direct thrombin inhibitors may mean a shift in first-line therapy in the very near future. Invasive therapies such as catheter-directed thrombolysis have also shown promise in the treatment of venous thrombosis and will likely see increased use in the future.
Export Options
About this article
Cite this article as:
Bain Jonathan, Oyler R. Douglas, Smyth S. Susan and Macaulay E. Tracy, Pathophysiology and Pharmacologic Treatment of Venous Thromboembolism, Current Drug Targets 2014; 15 (2) . https://dx.doi.org/10.2174/13894501113146660226
DOI https://dx.doi.org/10.2174/13894501113146660226 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Haploinsufficiency of DNA Damage Response Genes and their Potential Influence in Human Genomic Disorders
Current Genomics Smoking and Cardiovascular System: Cellular Features of the Damage
Current Pharmaceutical Design Novel Insights into the Pervasive Role of M3 Muscarinic Receptor in Cardiac Diseases
Current Drug Targets Indications for Heart Transplantation in Congenital Heart Disease
Current Cardiology Reviews Jean-Baptiste de Sénac’s (1693-1770) Important Work on Cardiology and Valvular Disorders
Current Pharmaceutical Design Review and Research on Feature Selection Methods from NMR Data in Biological Fluids. Presentation of an Original Ensemble Method Applied to Atherosclerosis Field
Current Drug Metabolism Mannose Conjugated Starch Nanoparticles for Preferential Targeting of Liver Cancer
Current Drug Delivery Neuroprotection by Methylene Blue in Cerebral Global Ischemic Injury Induced Blood-Brain Barrier Disruption and Brain Pathology: A Review
CNS & Neurological Disorders - Drug Targets Editorial (Thematic Issue: The Acute Management of Pediatric Heart Failure)
Current Cardiology Reviews Molecular Imaging: Its Application In Cardiovascular Diagnosis
Current Pharmaceutical Design Manual Thrombectomy During Primary Coronary Intervention in Acute Myocardial Infarction: A Brief Review
Reviews on Recent Clinical Trials Potential Targets for Intervention in Radiation-Induced Heart Disease
Current Drug Targets Q Fever Endocarditis
Infectious Disorders - Drug Targets The Role of Mitochondria in Piperine Mediated Cardioprotection in Isoproterenol Induced Myocardial Ischemia
Current Pharmaceutical Design Nano Cocrystals: Crystal Engineering from a Nanotechnological Perspective
Current Pharmaceutical Design Targeting JAK/STAT Signaling Pathway in Inflammatory Diseases
Current Signal Transduction Therapy Rewiring the Heart: Stem Cell Therapy to Restore Normal Cardiac Excitability and Conduction
Current Stem Cell Research & Therapy Cardiovascular Benefit of SGLT2 Inhibitors in the Therapeutics of Diabetes Mellitus: A Close Look beyond the Horizon
Current Drug Targets Platelet Resistance to the Anti-Aggregating Agents in the Insulin Resistant States
Current Diabetes Reviews The Role of iNOS in Chronic Inflammatory Processes In Vivo: Is it Damage-Promoting, Protective, or Active at all?
Current Molecular Medicine